EN DE
Watch AtriCure, Inc. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

AtriCure, Inc. (ATRC) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of AtriCure, Inc. stock $20.87, price $56.84, that is 63.3% below the price, quality 68 out of 100. Rating: strongly overvalued. Calculated from audited financials with 10 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US04963C2098

AI AtriCure, Inc. logo Some data Nov 12, 2026

AtriCure, Inc.

ATRC · US

Far too expensive (fair value 63% below the price), but solid company and rising price: meets 2 of 3 rules.

Get notified free when this changes
Quality 68/100 
Rising price (uptrend) 
Low debt 
Generates free cash flow 
Recent news mostly positive 
Revenue last quarter +15% vs. a year ago. 
Mixed Growth (revenue 5y +20.9 %/yr in USD) 
Thin margins · 2.5% net margin (TTM) 
Insiders sold $4.2M (6M) 
Some data 
Fair value $20.87 · Strongly overvalued 
Trails peers (2/14) 
Narrow moat 38/100
Watch AtriCure, Inc. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$87.14 $19.86 Fair Value $20.87 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 12, 2026.

How to read this chart

60‑month range $19.86 – $87.14 · fair‑value band $12.36 – $33.31 · the $56.84 price screens above the $20.87 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 12, 2026.

Follow AtriCure in your weekly email

Every Wednesday you see whether AtriCure is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally.

Show moreShow less

It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation.

It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters.

In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

Stock analysis

AtriCure, Inc. (ATRC) currently trades at $56.84, while our model-based Fair Value estimate is $20.87, 63% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of $23.71 per share, and 0 of the 10 models we run sit above the $56.84 price.

Bear case: the Asset-Based group reads lowest at $3.15, and 10 of the 10 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $12.36 (bear) to $33.31 (bull), the price of $56.84 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 68/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

AtriCure, Inc. reported revenue of $535M in FY2025 versus $274M in FY2021, a compound +18.1%/yr. Reported net income was −$11.4M in FY2025.

Key figures

Market cap $3.0B Mid · P/E ratio 183.4 · P/S ratio 5.14 · EPS (TTM) $0.3100 · Net margin 2.5% · Return on equity 3.0% · Return on assets (EBIT) −2.0% (5-year average) · Operating margin 2.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (medium confidence).

What moves the price

The share trades about 13% below its 52-week high and 120% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −43% fair-value upside, at −63%, ATRC screens richer than that median.

Fair Value models

Bear $12.36 Fair Value $20.87 Bull $33.31
Price $56.84 · Downside -63.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($0.2701 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $15.51 $24.93 $48.02 77
Growth DCF $15.00 $26.73 $44.77 76
5Y EBITDA Exit $8.69 $12.61 $17.65 75
All 10 models by family
DCF Models
FCF DCF $15.51 $24.93 $48.02 77
5Y Revenue Exit $12.36 $20.87 $33.31 71
5Y EBITDA Exit $8.69 $12.61 $17.65 75
10Y Revenue Exit $13.01 $21.73 $35.15 65
10Y EBITDA Exit $10.91 $15.63 $22.83 68
Multiples
EV/EBITDA $5.08 $6.26 $7.43 67
EV/Revenue $10.19 $13.89 $17.58 54
Asset-Based
NCAV (Graham) $2.08 $3.15 $3.93 55
Growth DCF
Growth DCF $15.00 $26.73 $44.77 76
Rev-Margin DCF $12.36 $20.69 $32.56 71

Open the full fair value analysis →

Quality Score breakdown

Overall quality 68/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 37
How much profit the company makes from its sales and capital
Quality Growth 78
Are margins and returns getting better?
Cashflow 58
Do the profits arrive as real cash?
Financial strength 95
Debt, balance sheet and risk of trouble
Investment 90
Does it invest with discipline instead of growing at any price?
Low Volatility 37
How calm the share price moves, does not count
Price momentum 95
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 89
Distance to the 52-week high, does not count
New shares 58
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 9 officers or directors sold shares worth $4.2M and none bought.

  • SaleB Kristine JohnsonDirector2,452 shares at $58.48$143,393Nov 6, 2026
  • SaleSalvatore PriviteraChief Technical Officer4× since Sep 2, 2026: 24,343 shares, avg. $58.58$1.4MNov 4, 202610b5-1 plan
  • SaleRegina E GrovesDirector5,313 shares at $54.22$288,071Sep 11, 2026
  • SaleKarl S. DahlquistChief Legal Officer9,370 shares at $48.89$458,099Aug 24, 2026
  • SaleKaren PrangeDirector2× since May 20, 2026: 6,564 shares, avg. $34.16$224,233Aug 5, 2026
  • SaleMaggie YuenDirector2× since Nov 21, 2025: 6,500 shares, avg. $37.17$241,630Aug 5, 2026
  • SaleJustin J NozneskyChief Mktg & Strategy Officer2× since Nov 26, 2025: 11,348 shares, avg. $38.11$432,502Jul 29, 2026
  • SaleSven WehrweinDirector2× since Nov 24, 2025: 35,000 shares, avg. $37.79$1.3MJul 28, 2026
  • SaleVinayak DoraiswamyChief Scientific Officer3× since Mar 12, 2026: 16,000 shares, avg. $32.69$523,080Jul 28, 2026

Plus 15 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 13, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 81/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+14.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+20.9%
Start year 2020 (pandemic). Over 10 years: +15.2% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+52.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−21.4% (2020) → −0.6% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+30.7%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+10.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +27.7% a year for the price and +8.3% for the forecasts.
Forecast 2026 (sales)+13.4%
Forecast 2027 (sales)+12.2%
Projected 2028 (sales)+11.0%
Projected 2029 (sales)+9.7%
Projected 2030 (sales)+8.4%

ATRC screens overvalued: fair value 63% below the price. Compare with Intuitive Surgical, Inc →

Recent news

News mood ⓘNews mood, the average tone of recent news (96 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.
Note from the team Oct 20, 2026
AI conclusion: High gross margins from differentiated disposable devices in niche cardiac procedures form the main strength, while persistent net losses and negative returns mark the key weakness in business durability.
Main risk: Failure to secure broader surgeon adoption or sufficient new clinical evidence would constrain volume growth in its core atrial fibrillation and left atrial appendage devices.
AtriCure generates most revenue from high-margin disposable devices used in atrial fibrillation and left atrial appendage procedures. Consistent double-digit growth in those procedures has lifted results, yet sustaining that pace depends on broader surgeon adoption and fresh clinical evidence. Will ongoing trials accelerate volume enough to ease valuation pressure or leave growth more incremental than expected?
Join the discussion →

Compare AtriCure, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 199 stocks

Beats the industry median on 2/14 measures
Overall it trails its industry peers.
Valuation
Quality Score 68 · Top 25%
Fair Value upside −63.3% · Bottom 25%
Profitability
Return on equity (12 months) 3.0% · Below median
Return on assets −1.8% · Below median
Net margin (12 months) 2.5% · Below median
Operating margin (12 months) 2.8% · Below median
Growth and dividend
Revenue growth (quarter YoY) 15.0% · Above median
Balance sheet
Debt / equity 0.13× · Above median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/E (12 months) 183.4× · Priciest 25%
P/B 6.16× · Priciest 25%
P/S (12 months) 5.14× · Priciest 25%
Price / free cash flow (fiscal year) 62.8× · Priciest 25%
EV/EBITDA 76.8× · Priciest 25%
PEG 10.00× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 16
FUTURE (revenue growth)75 · sector 39
PAST (return on equity)12 · sector 26
HEALTH (low debt)94 · sector 96
DIVIDEND (yield)0 · sector 31

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $89.08 $131.27 +47% vs ATRC
EssilorLuxottica Société anonyme EL €182.35 €196.22 +8% vs ATRC
Intuitive Surgical, Inc ISRG $443.59 $353.90 −20% vs ATRC
Medline Inc MDLN $39.47 $28.59 −28% vs ATRC
Alcon Inc ALC CHF 61.36 CHF 34.91 −43% vs ATRC
Becton, Dickinson and Company BDX $218.03 $97.80 −55% vs ATRC
Straumann Holding STMN CHF 107.20 CHF 45.50 −58% vs ATRC
West Pharmaceutical Services, Inc WST $416.42 $139.22 −67% vs ATRC
Sartorius Stedim Biotech S.A DIM €223.20 €54.82 −75% vs ATRC
Sartorius Aktiengesellschaft SRT €225.50 €46.44 −79% vs ATRC

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

AtriCure, Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "AtriCure, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/ATRC

Frequently asked questions

Is AtriCure, Inc. (ATRC) overvalued or undervalued?
As of Nov 12, 2026, our model estimates a fair value of $20.87 versus a price of $56.84, about 63% lower (overvalued).
What is the fair value of ATRC?
Our model-based fair value for AtriCure, Inc. is $20.87 (as of Nov 12, 2026), built from audited fundamentals. The current price: $56.84.
What is the quality score of ATRC?
AtriCure, Inc. has a Quality Score of 68/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for AtriCure, Inc. (ATRC)?
Our model-based price target is the fair value of $20.87 (as of Nov 12, 2026) from 10 valuation models. Cautious scenario $12.36, optimistic scenario $33.31. It is a calculation from audited fundamentals, not an analyst target.
What is the AtriCure, Inc. stock forecast for 2026?
Our models put fair value at $20.87, about 63% lower versus a price of $56.84 (overvalued). Cautious scenario $12.36, optimistic scenario $33.31. The calculation is refreshed regularly with new filings.
What is the revenue of AtriCure, Inc. (ATRC)?
AtriCure, Inc. reported trailing-twelve-month revenue of about $590M (latest available figure, as of Nov 12, 2026).
What growth is priced into AtriCure, Inc. (ATRC)?
For today's price to be fair in a discounted-cash-flow model, AtriCure, Inc. would have to grow free cash flow by +30.7 % per year for five years (discount rate 10.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +21.0 % per year. As of Nov 12, 2026.
What discount rate (WACC) does the fair value of ATRC use?
Our models discount AtriCure, Inc. at 10.2 %: a base by market capitalisation (mid), damped by beta 1.21, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For AtriCure, Inc. that is +30.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.2 %) and the same formula as our fair value.
How much growth has AtriCure, Inc. (ATRC) delivered so far?
Over the past 5 years revenue at AtriCure, Inc. grew +21.0 % a year. The price currently implies free-cash-flow growth of +30.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of AtriCure, Inc. (ATRC) growing?
The median revenue growth in the sector is +5.8 % a year. That is the yardstick for the growth priced into AtriCure, Inc. (+30.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of AtriCure, Inc. (ATRC)?
The free-cash-flow yield on the price is 1.73 %: that much free cash flow AtriCure, Inc. produces per unit of market value. When it exceeds the discount rate of our models (10.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of AtriCure, Inc. (ATRC)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For AtriCure, Inc. it is $20.87 per share (as of Nov 12, 2026), against a price of $56.84. It is the blended result of 10 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is AtriCure, Inc. stock overvalued or undervalued in 2026?
As of Nov 12, 2026, ATRC trades above its calculated fair value: price $56.84, fair value $20.87, a gap of about −63% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ATRC?
No. The price is what the market pays today ($56.84); the fair value is what the company's own numbers justify ($20.87). For AtriCure, Inc. the two are $35.97 per share apart. That gap is exactly why we show both numbers side by side.
How much is AtriCure, Inc. worth?
The market values AtriCure, Inc. at about $3.0B (market capitalisation, as of Nov 12, 2026). Per share that is $56.84; our models calculate a fair value of $20.87 per share.
What do the bullish and bearish scenarios say about ATRC?
Our models span a range for AtriCure, Inc.: cautious scenario $12.36, base $20.87, optimistic $33.31 per share (as of Nov 12, 2026, price $56.84). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ATRC?
AtriCure, Inc. trades at a price-to-earnings ratio of 183.4 (as of Nov 12, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $20.87 is built from several models across several years. Other multiples: PEG 10.0, P/B 6.2, P/S 5.1, EV/EBITDA 76.8.
What is the PEG ratio of ATRC?
The PEG ratio of AtriCure, Inc. is 10.00 (P/E divided by earnings growth, as of Nov 12, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of AtriCure, Inc. (ATRC)?
Balance-sheet figures for AtriCure, Inc. (as of Nov 12, 2026): return on equity 3.0%, debt of 0.13 per unit of equity. They feed the Quality Score of 68/100, which measures business quality independently of the share price.
How far is ATRC from its 52-week high?
AtriCure, Inc. trades at $56.84, about 13% below its 52-week high of $65.53 and 120% above the low of $25.86 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of $20.87 is for.
Which stocks are comparable to AtriCure, Inc.?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is AtriCure, Inc. stock attractive at the current price?
The data as of Nov 12, 2026: price $56.84, calculated fair value $20.87 (−63%), Quality Score 68/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ATRC calculated?
We run AtriCure, Inc. through 10 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of $20.87 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9% above its aggregate fair value. AtriCure, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of AtriCure, Inc. (ATRC)?
The closing price on Nov 13, 2026 was $56.84. Our model-based fair value is $20.87, about 63% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with AtriCure, Inc. right now?
The price sits above even our optimistic bull case ($33.31). The favourable scenario is already priced in. The model range is unusually wide ($12.36 to $33.31). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (68/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of AtriCure, Inc.

How large is the market capitalisation of AtriCure, Inc. (ATRC)?
The market capitalisation of AtriCure, Inc. is $3.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of AtriCure, Inc. (ATRC)?
The price-to-sales ratio of AtriCure, Inc. is 5.14 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of AtriCure, Inc. (ATRC)?
Earnings per share at AtriCure, Inc. are $0.3100 (price ÷ EPS = P/E 183.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of AtriCure, Inc. (ATRC)?
The net margin of AtriCure, Inc. is 2.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of AtriCure, Inc. (ATRC)?
The return on equity (ROE) of AtriCure, Inc. is 3.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of AtriCure, Inc. (ATRC)?
On an EBIT basis the return on assets of AtriCure, Inc. is −2.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of AtriCure, Inc. (ATRC)?
The operating margin of AtriCure, Inc. is 2.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at AtriCure, Inc. (ATRC)?
Revenue at AtriCure, Inc. is growing +15.0% versus a year earlier (3y avg +17.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net cash does AtriCure, Inc. (ATRC) hold?
AtriCure, Inc. holds more cash than debt, $79.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch AtriCure, Inc. in the live analysis

One click puts AtriCure, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.